@prefix this: <http://www.tkuhn.ch/bel2nanopub/RA_CPaKXjDhunIFjVt5odUZst1bXZruBGJuxIPabWqj5M> .
@prefix sub: <http://www.tkuhn.ch/bel2nanopub/RA_CPaKXjDhunIFjVt5odUZst1bXZruBGJuxIPabWqj5M#> .
@prefix beldoc: <http://resource.belframework.org/belframework/1.0/knowledge/large_corpus.bel> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .
@prefix dct: <http://purl.org/dc/terms/> .
@prefix dce: <http://purl.org/dc/elements/1.1/> .
@prefix pav: <http://purl.org/pav/> .
@prefix np: <http://www.nanopub.org/nschema#> .
@prefix belv: <http://www.selventa.com/vocabulary/> .
@prefix prov: <http://www.w3.org/ns/prov#> .
@prefix chebi: <http://www.ebi.ac.uk/chebi/searchId.do?chebiId=> .
@prefix sdis: <http://resource.belframework.org/belframework/1.0/namespace/selventa-legacy-diseases/> .
@prefix mesh: <http://purl.bioontology.org/ontology/MSH/> .
@prefix occursIn: <http://purl.obolibrary.org/obo/BFO_0000066> .
@prefix species: <http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?id=> .
@prefix pubmed: <http://www.ncbi.nlm.nih.gov/pubmed/> .
@prefix orcid: <http://orcid.org/> .

sub:Head {
  this: np:hasAssertion sub:assertion;
    np:hasProvenance sub:provenance;
    np:hasPublicationInfo sub:pubinfo;
    a np:Nanopublication .
}

sub:assertion {
  sub:_1 occursIn: mesh:D009132, species:9606;
    rdf:object sdis:muscle%20glucose%20import;
    rdf:predicate belv:increases;
    rdf:subject chebi:9753;
    a rdf:Statement .
  
  sub:assertion rdfs:label "a(CHEBI:troglitazone) -> path(SDIS:\"muscle glucose import\")" .
}

sub:provenance {
  beldoc: dce:description "Approximately 61,000 statements.";
    dce:rights "Copyright (c) 2011-2012, Selventa. All rights reserved.";
    dce:title "BEL Framework Large Corpus Document";
    pav:authoredBy sub:_3;
    pav:version "1.4" .
  
  sub:_2 prov:value "Addition of a sulfonylurea to metformin therapy gives an additive glucose- lowering effect (102, 103,149). Similarly, addition of metformin to sulfonylurea therapy gives an additive response, both with respect to glucose-lowering (101, 103, 149-152) and lipid-lowering (91, 103) effects the elevated fasting plasma glucose level is caused by incomplete suppression of basal hepatic glucose production by sulfonylurea or metformin Figure 1. Pathogenesis of type 2 diabetes mellitus. Sites of action of oral agents are indicated. A negative sign indicates inhibition; a positive sign indicates stimulation.";
    prov:wasQuotedFrom pubmed:10454950 .
  
  sub:_3 rdfs:label "Selventa" .
  
  sub:assertion prov:hadPrimarySource pubmed:10454950;
    prov:wasDerivedFrom beldoc:, sub:_2 .
}

sub:pubinfo {
  this: dct:created "2014-07-03T14:29:48.171+02:00"^^xsd:dateTime;
    pav:createdBy orcid:0000-0001-6818-334X, orcid:0000-0002-1267-0234 .
}